Jounce Therapeutics Inc (JNCE) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Jounce Therapeutics Inc (NASDAQ:JNCE) have been assigned a consensus rating of “Hold” from the nine research firms that are presently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $13.20.

JNCE has been the subject of several analyst reports. ValuEngine raised shares of Jounce Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. JPMorgan Chase & Co. dropped their price target on shares of Jounce Therapeutics from $12.00 to $10.00 and set a “hold” rating for the company in a research note on Friday, August 10th. Robert W. Baird dropped their price target on shares of Jounce Therapeutics from $35.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, June 4th. Wells Fargo & Co dropped their price target on shares of Jounce Therapeutics to $10.00 and set a “market perform” rating for the company in a research note on Thursday, May 31st. Finally, Zacks Investment Research downgraded shares of Jounce Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th.

Hedge funds have recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC acquired a new stake in shares of Jounce Therapeutics during the first quarter worth $159,000. Schwab Charles Investment Management Inc. increased its position in shares of Jounce Therapeutics by 20.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 47,951 shares of the company’s stock worth $368,000 after buying an additional 8,103 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Jounce Therapeutics during the first quarter worth $243,000. Granahan Investment Management Inc. MA increased its position in shares of Jounce Therapeutics by 9.1% during the second quarter. Granahan Investment Management Inc. MA now owns 131,592 shares of the company’s stock worth $1,008,000 after buying an additional 11,007 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Jounce Therapeutics during the first quarter worth $313,000. 84.11% of the stock is owned by hedge funds and other institutional investors.

Shares of JNCE stock traded down $0.13 during trading hours on Wednesday, hitting $6.58. 133,300 shares of the company’s stock traded hands, compared to its average volume of 487,340. The company has a market capitalization of $217.30 million, a P/E ratio of -11.77 and a beta of 5.21. Jounce Therapeutics has a 12 month low of $6.26 and a 12 month high of $29.25.

Jounce Therapeutics (NASDAQ:JNCE) last released its quarterly earnings results on Friday, August 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.23. The firm had revenue of $19.38 million during the quarter, compared to the consensus estimate of $12.47 million. Jounce Therapeutics had a negative net margin of 50.54% and a negative return on equity of 23.27%. sell-side analysts expect that Jounce Therapeutics will post -1.26 earnings per share for the current year.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

Featured Story: Marijuana Stocks

Analyst Recommendations for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply